John Cronin leads a team of more than 1,300 professionals in highly dynamic, high-performance environments to deliver world-class biologics, cell and gene therapy and active pharmaceutical ingredient (API) manufacturing facilities.
John brings 37 years’ experience managing teams in his role, and draws on his deep experience in project delivery, coupled with a strategic focus on inclusion, innovation and sustainability.
-
37
years' experience, most of it managing high-performance teams
-
12
years at Jacobs, now leading a team of more than 1,300 based out of 5 operational offices (Dublin, Cork, Milan, Copenhagen, Basel)
John is particularly adept in full life-cycle industrial project delivery and has led some of our largest Life Sciences projects, including the Bristol Myers Squibb Large-Scale Cell Culture Manufacturing Facility in Cruiserath, Dublin, which deployed state‐of‐the‐art project and construction management techniques and tools.
This transformative project was delivered within budget, achieved an impressive safety record on more than 6,500,000 site hours. The project was the recipient of ISPE’s 2020 Facility of the Year Award for Project Execution, won the Industrial Category at the 2019 Irish Construction Excellence (ICE) Awards and received the Best Project Award from ENR.
Subsequent to the Bristol Myers Squibb project, John then took on the role of Project Director delivering a complex biotech manufacturing facility within the confines of a redundant hormonal medicine manufacturing plant for another client
John is a Chartered Engineer and Fellow of Engineers Ireland. He joined Jacobs as senior project manager in 2011 and has held multiple leadership roles within the organization.
Prior to his current appointment, he was Vice President and Executive Project Director, Life Sciences Ireland Operations and prior to that was Director of Engineering for the Ireland Operation.
Supporting Life Sciences projects is hugely motivating for John, and he feels deeply connected to the purpose of these projects in manufacturing complex medicines and treatments that have the potential to benefit patients worldwide.